Investors, in particular, would do well to recall that safety is the catchword. Some may argue the pendulum at the FDA has swung too far in one direction, so far that, perhaps, some agency staffers are overly zealous. But unless or until a drug can deliver a clear benefit with minimal risk, no one should expect a bumper crop of new diet drugs anytime soon.
via seekingalpha.com
No comments:
Post a Comment